FIELD: pharmaceutics.
SUBSTANCE: present group of inventions relates to a new crystalline solvate form IV of cortexolone-17α-propionate, a method for production thereof and a pharmaceutical composition based thereon. Crystalline solvate form IV of cortexolone-17α-propionate is shown on fig. 30. Crystalline solvate form IV of cortexolone-17α-propionate is obtained by crystallisation of the latter from a mixture of propylene glycol/water at the ratio of 1/1 or from a mixture of polyethylene glycol/water at the ratio of 1/1.
EFFECT: combination of the said crystalline solvate form and at least one physiologically acceptable additive is used in pharmaceutics to treat urogenital pathologies, endocrine system pathologies, skin and/or skin appendages.
8 cl, 30 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORMS OF CORTEXOLONE-17α-PROPIONATE AND METHOD FOR PREPARING THEM | 2008 |
|
RU2482190C2 |
| 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN TREATMENT OF TUMOURS | 2015 |
|
RU2712950C2 |
| 17A, 21-DIESTERS OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2821529C2 |
| 17ALPHA-BENZOATE OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2712752C2 |
| METHOD FOR OBTAINING FLUTICASONE PROPIONATE OBTAINING, PARTICULARLY POLYMORPHOUS FORM 1 | 2003 |
|
RU2333218C2 |
| HIGHLY CONCENTRATED COMPOSITION | 2016 |
|
RU2731564C2 |
| METHODS FOR PREPARING CABERGOLINE CRYSTALLINE FORM I AND V, METHOD FOR PREPARING CABERGOLINE SOLVATED FORM V | 2003 |
|
RU2278118C2 |
| PROCESS FOR PREPARING 16-α-METHYLATED STEROIDS | 1993 |
|
RU2125575C1 |
| METHOD OF OBTAINING 11BETA, 17 ALPHA, 21-TRIHYDROXY-16ALPHA-METHYL-9ALPHA-FLUOROPREGNA-1,4-DIENE-3,20-DIONE (DEXAMETHAZONE) FROM PHYTOSTEROL | 2013 |
|
RU2532902C1 |
| DOCETAXEL POLYMORPHS AND SYNTHESIS METHODS THEREOF | 2007 |
|
RU2437875C2 |
